Pancreas · Vol. 1, No. 2 · 2025 · pp. e8–e10 · e-ISSN 2471-142X

ADAM10 Proteases and Pancreatic Cancer

Jaya Padmanabhan, PhD

DOI: https://doi.org/10.17140/poj-1-e003 · Published 2025-09-08 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2025 The Author(s)

Also available as PDF (figures and tables appear in the PDF).

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related deaths in the United States and is expected to rise to the second rank by 2020.1 The survival rate of PDAC is estimated at less than 5% and the high mortality rate is attributed to the as-ymptomatic progression and aggressive nature of the tumor, which exhibit locally advanced or metastatic disease at the time of diagnosis. Majority of the pancreatic cancers are PDACs and are characterized by a fibrotic tumor stroma.

Keywords: toxicity issues, and therefore additional strategies are being developed to effectively treat PDAC

Acknowledgements

The studies in JP’s lab is supported by grants from Anna Valentine Collaborative Grant and Byrd Institute Small Grant Program.

References

  1. SiegelRNaishadhamDJemalA. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1): 10-29. doi: 10.3322/caac.20138 rd10.3322/caac.20138 https://doi.org/10.3322/caac.20138
  2. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1997; 15(6): 2403-2413
  3. Berlin J and Benson AB, 3rd. Chemotherapy: gemcitabine remains the standard of care for pancreatic cancer. Nat Rev Clin Oncol. 2010; 7(3): 135-137. doi: 10.1038/nrclinonc.2010.16 https://doi.org/10.1038/nrclinonc.2010.16
  4. KorcM. Pancreatic cancer-associated stroma production. Am J Surg. 2007; 194(4 Suppl): S84-S86. doi: 10.1016/j.amjsurg.2007.05.00410.1016/j.amjsurg.2007.05.004 https://doi.org/10.1016/j.amjsurg.2007.05.004
  5. Marks E, Saif MW and Jia Y. Updates on first-line therapy for metastatic pancreatic adenocarcinoma. JOP: Journal of the pancreas. 2014; 15(2): 99-102. doi: 10.6092/1590-8577/2279 https://doi.org/10.6092/1590-8577/2279
  6. ConroyTDesseigneFYchouM. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine. 2011; 364(19): 1817-1825. doi: 10.1056/NEJMoa101192310.1056/nejmoa1011923 https://doi.org/10.1056/nejmoa1011923
  7. CrawfordHCDempseyPJBrownGAdamLMossML. ADAM10 as a therapeutic target for cancer and inflammation. Current Pharmaceutical Design. 2009; 15(20): 2288-2299. doi: 10.2174/13816120978868244210.2174/138161209788682442 https://doi.org/10.2174/138161209788682442
  8. MossMLStoeckAYanWDempseyPJ. ADAM10 as a target for anti-cancer therapy. Current Pharmaceutical Biotechnology. 2008; 9(1): 2-8
  9. Seals DF and Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003; 17(1): 7-30. doi: 10.1101/gad.1039703 https://doi.org/10.1101/gad.1039703
  10. NakamuraHSuenagaNTaniwakiK. Constitutive and induced CD44 shedding by ADAM-like proteases and membranetype 1 matrix metalloproteinase. Cancer Research. 2004; 64(3): 876-882. doi: 10.1158/0008-5472.CAN-03-350210.1158/0008-5472.can-03-3502 https://doi.org/10.1158/0008-5472.can-03-3502
  11. ReissKMaretzkyTLudwigA. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. The EMBO journal. 2005; 24(4): 742-752. doi: 10.1038/sj.emboj.760054810.1038/sj.emboj.7600548 https://doi.org/10.1038/sj.emboj.7600548
  12. MaretzkyTReissKLudwigA. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(26): 9182-9187. doi: 10.1073/pnas.050091810210.1073/pnas.0500918102 https://doi.org/10.1073/pnas.0500918102
  13. WoodsNKPadmanabhanJ. Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells. The Journal of Biological Chemistry. 2013. doi: 10.1074/jbc.M113.45925510.1074/jbc.m113.459255 https://doi.org/10.1074/jbc.m113.459255
  14. GaidaMMHaagNGuntherF. Expression ofA disintegrin and metalloprotease 10 in pancreatic carcinoma. Int J Mol Med. 2010; 26(2): 281-288. doi: 10.3892/ijmm_0000046310.3892/ijmm_00000463 https://doi.org/10.3892/ijmm_00000463
  15. Sebens Muerkoster S, Werbing V, et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene. 2007; 26(19): 2759-2768. doi: 10.1038/ sj.onc.1210076
  16. WenteMNGaidaMMMayerC. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol. 2008; 33(2): 297-308. doi: 10.3892/ijo_0000000910.3892/ijo_00000009 https://doi.org/10.3892/ijo_00000009
  17. RingelJRychlyJNebeB. CD44, bFGF and hyaluronan in human pancreatic cancer cell lines. Annals of the New York Academy of Sciences. 1999; 880: 238-242. doi: 10.1111/j.1749-6632.1999.tb09528.x10.1111/j.1749-6632.1999.tb09528.x https://doi.org/10.1111/j.1749-6632.1999.tb09528.x
  18. WoodsNTrevinoJCoppolaDChellappanSYangSPadmanabhanJ. Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and beta-catenin signaling. Oncotarget. 2015; 6(34): 35931-35948
  19. WojtalewiczNSadeqzadehEWeissJV. A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding. PloS One. 2014; 9(3): e90461. doi: 10.1371/journal.pone.009046110.1371/journal.pone.0090461 https://doi.org/10.1371/journal.pone.0090461
  20. SingATsatskisYFabianL. The atypical cadherin fat directly regulates mitochondrial function and metabolic state. Cell. 2014; 158(6): 1293-1308. doi: 10.1016/j.cell.2014.07.03610.1016/j.cell.2014.07.036 https://doi.org/10.1016/j.cell.2014.07.036
  21. TanoueTTakeichiM. Mammalian Fat1 cadherin regulates actin dynamics and cell-cell contact. The Journal of Cell Biology. 2004; 165(4): 517-528. doi: 10.1083/jcb.20040300610.1083/jcb.200403006 https://doi.org/10.1083/jcb.200403006